Sarafem patent ruling
Executive Summary
A Sarafem (fluoxetine) use patent is valid and infringed by Teva's ANDA, an Indianapolis federal judge rules. Patent no. 4,971,998, which claims a method for using fluoxetine to treat disturbances of mood or appetite, depression or carbohydrate craving associated with premenstrual syndrome, is neither anticipated nor obvious, court says. The patent expires in May 2008 following a six-month pediatric extension. Sarafem, a repackaged version of Prozac, was launched by Lilly in August 2000 for the treatment of premenstrual dysphoric disorder; the product was divested to Galen/Warner Chilcott in 2002 (1"The Pink Sheet" Dec. 16, 2002, p. 34). Prozac generics entered the market in 2001...
You may also be interested in...
Lilly Sells Sarafem: Galen Adds Drug To Women’s Health Line For $295 Mil.
Galen is adding Sarafem to its line of women's health products through a $295 mil. deal with Lilly
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.